Jefferies Group LLC reiterated their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a research report released on Friday, July 14th. They currently have a $26.00 price target on the biotechnology company’s stock.
A number of other research firms also recently weighed in on HRTX. Aegis reissued a buy rating on shares of Heron Therapeutics in a research report on Tuesday, March 21st. Cantor Fitzgerald reaffirmed an overweight rating on shares of Heron Therapeutics in a research report on Monday, June 26th. Zacks Investment Research raised shares of Heron Therapeutics from a hold rating to a buy rating and set a $14.00 price objective for the company in a research report on Wednesday, July 12th. Cowen and Company reaffirmed a buy rating and set a $40.00 price objective on shares of Heron Therapeutics in a research report on Friday, May 26th. Finally, ValuEngine raised shares of Heron Therapeutics from a strong sell rating to a sell rating in a research report on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company’s stock. Heron Therapeutics currently has an average rating of Buy and an average price target of $31.00.
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 16.00 on Friday. The company’s 50-day moving average is $15.38 and its 200-day moving average is $14.57. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $22.01.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.10. The firm had revenue of $8.51 million for the quarter, compared to analyst estimates of $4.53 million. Equities analysts predict that Heron Therapeutics will post ($3.74) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Rating Reaffirmed by Jefferies Group LLC” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/08/12/heron-therapeutics-nasdaqhrtx-buy-rating-reaffirmed-at-jefferies-group-llc-updated-updated-updated.html.
Several large investors have recently added to or reduced their stakes in HRTX. Swiss National Bank boosted its stake in Heron Therapeutics by 39.9% in the first quarter. Swiss National Bank now owns 72,600 shares of the biotechnology company’s stock worth $1,089,000 after buying an additional 20,700 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Heron Therapeutics by 27.1% in the first quarter. Bank of New York Mellon Corp now owns 190,771 shares of the biotechnology company’s stock valued at $2,861,000 after buying an additional 40,657 shares during the period. Falcon Point Capital LLC purchased a new stake in shares of Heron Therapeutics during the first quarter valued at $501,000. Searle & CO. purchased a new stake in shares of Heron Therapeutics during the first quarter valued at $353,000. Finally, Wells Fargo & Company MN raised its stake in shares of Heron Therapeutics by 78.8% in the first quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 17,442 shares during the period.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
What are top analysts saying about Heron Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics Inc. and related companies.